Press releasePRNewswire
Nektar Therapeutics
NKTR · NASDAQ
$39.22+$2.58 (+7.04%)TodayMarket closed ·
Prev close $36.64
Latest news
- Press releasePRNewswire
/UPDATE -- Nektar Therapeutics/
- Press releasePRNewswire
New Biomarker Data Presented in a Late Breaking Oral Presentation at EADV Congress 2026 Showing Early Molecular Responses to Rezpegaldesleukin Across Multiple Immune Pathways Dysregulated in Patients with Atopic Dermatitis
- Press releasePRNewswire
Nektar Announces Three Oral Presentations for Rezpegaldesleukin at the European Academy of Dermatology & Venereology (EADV) Congress 2026
- Press releasePRNewswire
Nektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- NewsVandana Singh
Eli Lilly Did Breach Implied Covenant of Good Faith With Nektar Therapeutics, Jury Funds
- Press releasePRNewswire
Nektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- News
Nektar Therapeutics Announces Publication Of Peer-Reviewed Data From 16-Week Induction Period Of REZOLVE-AD, Phase 2b Study Evaluating Rezpegaldesleukin In Adults With Moderate-To-Severe Atopic Dermatitis
- Press releasePRNewswire
Nektar Announces Publication in The Lancet of Positive Phase 2b REZOLVE-AD 16-Week Induction Results of Rezpegaldesleukin in Moderate-to-Severe Atopic Dermatitis
- News
Full Transcript: Nektar Therapeutics Q2 2026 Earnings Call
- Press releasePRNewswire
Nektar Therapeutics Announces Second Quarter 2026 Financial Results
- Press releasePRNewswire
Kuehn Law Encourages Investors of Nektar Therapeutics to Contact Law Firm
- Press releasePRNewswire
Nektar Therapeutics to Announce Financial Results for the Second Quarter on Thursday, August 13, 2026, After Close of U.S.-Based Financial Markets
- Press releasePRNewswire
Nektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Press releasePRNewswire
Nektar Therapeutics Announces Start of Phase 3 ZENITH AD Program Evaluating Novel Regulatory T-Cell Biologic Rezpegaldesleukin in Moderate-to-Severe Atopic Dermatitis
- Press releasePRNewswire
Nektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Press releasePRNewswire
Nektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Press releasePRNewswire
Nektar Therapeutics to Participate in the 2026 Jefferies Global Healthcare Conference in New York
- Press releasePRNewswire
Nektar Therapeutics Reports First Quarter 2026 Financial Results
- Press releaseGlobe Newswire
Pomerantz Law Firm Announces the Filing of a Class Action Against Nektar Therapeutics and Certain Officers – NKTR
- Press releaseGlobe Newswire
Deadline Alert: Nektar Therapeutics (NKTR) Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP About Securities Fraud Lawsuit
- Press releasePRNewswire
NKTR UPCOMING DEADLINE: Faruqi & Faruqi, LLP Reminds Nektar Therapeutics (NKTR) Investors of Securities Class Action Deadline on May 5, 2026
- Press releasePRNewswire
The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of May 5, 2026 in Nektar Therapeutics Lawsuit - NKTR
- Press releasePRNewswire
NKTR Deadline: NKTR Investors Have Opportunity to Lead Nektar Therapeutics Securities Fraud Lawsuit
- Press releaseGlobe Newswire
NKTR Investor Alert: Nektar Therapeutics Securities Fraud Lawsuit - Investors With Losses May Seek to Lead the Class Action After Allegedly Misrepresenting Enrollment Protocol Compliance: Levi & Korsinsky
- Press releaseGlobe Newswire
NEKTAR THERAPEUTICS CLASS ACTION REMINDER: Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Against Nektar Therapeutics and Encourages Investors to Contact the Firm Before May 5th
- Press releaseBusiness Wire
Deadline Soon: Nektar Therapeutics (NKTR) Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz About Securities Fraud Lawsuit
- Press releasePRNewswire
Nektar Therapeutics Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - NKTR
- Press releasePRNewswire
NKTR Investors Have Opportunity to Lead Nektar Therapeutics Securities Fraud Lawsuit with the Schall Law Firm
- Press releasePRNewswire
NKTR Investor Alert: Nektar Therapeutics Securities Fraud Lawsuit - Investors With Losses May Seek to Lead the Class Action After Allegedly Misrepresenting Trial Data Integrity: SueWallSt
- Press releasePRNewswire
NKTR Investor Alert: Nektar Therapeutics Securities Fraud Lawsuit - Investors With Losses May Seek to Lead the Class Action After Zalevsky Allegedly Overstated Enrollment Compliance: Levi & Korsinsky
- Press releasePRNewswire
Nektar to Announce Financial Results for the First Quarter on Thursday, May 7, 2026, After Close of U.S.-Based Financial Markets
- Press releasePRNewswire
NKTR Investor Alert: Nektar Therapeutics Securities Fraud Lawsuit - Investors With Losses May Seek to Lead the Class Action After Allegedly Concealing Known Trial Defects: SueWallSt
- NewsDylan Berman
Why Are Nektar Shares Up Monday?
- Press releasePRNewswire
NKTR Investor Alert: Nektar Therapeutics Securities Fraud Lawsuit - Investors With Losses May Seek to Lead the Class Action After Allegedly Hiding Enrollment Protocol Failures: SueWallSt
- Press releasePRNewswire
NKTR Investor Alert: Nektar Therapeutics Securities Fraud Lawsuit - Investors With Losses May Seek to Lead the Class Action After Allegedly Hiding Enrollment Protocol Failures: SueWallSt
- News
Nektar Therapeutics Q4 EPS $(1.78) Beats $(2.59) Estimate, Sales $21.807M Beat $10.404M Estimate
- News
Where Nektar Therapeutics Stands With Analysts
- NewsHenry Khederian
Nektar Therapeutics (NKTR) Stock Slides Despite Analyst Optimism On Alopecia Data
- NewsVandana Singh
Nektar Alopecia Trial Misses Endpoint, Hits Significance After Patient Exclusion
- NewsAvi Kapoor
Shoe Carnival, American Eagle, Ciena, Victoria's Secret And Other Big Stocks Moving Higher On Thursday
Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.